MCID: CNT017
MIFTS: 43

Central Nervous System Origin Vertigo

Categories: Ear diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Central Nervous System Origin Vertigo

MalaCards integrated aliases for Central Nervous System Origin Vertigo:

Name: Central Nervous System Origin Vertigo 11 14 71
Vertigo of Central Origin 11 31
Vertigo 43 75
Central Vestibular Vertigo 11

Classifications:



External Ids:

Disease Ontology 11 DOID:2479
ICD9CM 34 386.2
MeSH 43 D014717
SNOMED-CT 68 20425006
ICD10 31 H81.4
UMLS 71 C0155503

Summaries for Central Nervous System Origin Vertigo

Disease Ontology: 11 A brain disease that is characterized by vertigo caused by hemorrhagic insult, ischemic insult or mass lesion of the cerebellum, the vestibular nuclei, and the brainstem, has symptom dizziness, has symptom nausea, has symptom vomiting and has symptom difficulty walking.

MalaCards based summary: Central Nervous System Origin Vertigo, also known as vertigo of central origin, is related to sneddon syndrome and cerebrovascular disease, and has symptoms including vomiting, difficulty walking and nausea. An important gene associated with Central Nervous System Origin Vertigo is CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A), and among its related pathways/superpathways are Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) and Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs). The drugs Dopamine and Calcium carbonate have been mentioned in the context of this disorder. Affiliated tissues include cerebellum, brain and liver, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia: 75 Vertigo is a condition where a person has the sensation of movement or of surrounding objects moving... more...

Related Diseases for Central Nervous System Origin Vertigo

Diseases related to Central Nervous System Origin Vertigo via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 873)
# Related Disease Score Top Affiliating Genes
1 sneddon syndrome 31.3 SERPINC1 F2
2 cerebrovascular disease 30.4 PLG MTHFR F2
3 migraine with aura 30.3 MTHFR F2 CACNA1A
4 migraine with or without aura 1 30.3 POLG PLG MTHFR F2 CACNA1A ATP4A
5 facial paralysis 30.1 PLG ACE2
6 migraine without aura 30.1 MTHFR CACNA1A
7 cranial nerve palsy 30.0 SERPINC1 F2
8 transient cerebral ischemia 29.9 SERPINC1 PLG MTHFR F2
9 abducens palsy 29.9 SERPINC1 F2
10 ocular motility disease 29.8 POLG CACNA1A
11 apnea, obstructive sleep 29.8 ATP4A ATP12A
12 vitamin b12 deficiency 29.7 MTHFR ATP4A ATP12A
13 somatoform disorder 29.7 ATP4A ATP12A
14 mastoiditis 29.6 SERPINC1 MTHFR F2
15 stroke, ischemic 29.6 SERPINC1 PLG MTHFR F2 ACE2
16 cavernous hemangioma 29.5 SERPINC1 F2
17 behcet syndrome 29.5 SERPINC1 MTHFR F2
18 pernicious anemia 29.5 ATP4A ATP12A
19 chickenpox 29.4 F2 ACE2
20 intracranial hypotension 29.4 SERPINC1 MTHFR F2
21 thrombophilia due to thrombin defect 29.4 SERPINC1 MTHFR F2
22 eclampsia 29.4 SERPINC1 MTHFR F2
23 dysentery 29.4 ATP4A ATP12A
24 antiphospholipid syndrome 29.4 SERPINC1 MTHFR F2
25 covid-19 29.3 PLG F2 ACE2
26 viral pneumonia 29.2 F2 ACE2
27 urinary tract infection 29.2 F2 ATP4A ATP12A
28 nutritional deficiency disease 29.2 MTHFR F2 ATP4A ATP12A
29 cerebral palsy 29.1 SERPINC1 MTHFR F2 CACNA1A
30 thrombophilia due to activated protein c resistance 28.9 SERPINC1 PLG MTHFR F2
31 budd-chiari syndrome 28.9 SERPINC1 PLG MTHFR F2
32 peripheral vascular disease 28.9 SERPINC1 PLG MTHFR F2
33 atrial heart septal defect 28.9 SERPINC1 PLG MTHFR F2
34 cardiovascular system disease 28.9 SERPINC1 PLG MTHFR ACE2
35 respiratory failure 28.6 SERPINC1 PLG F2 ACE2
36 deficiency anemia 28.5 SERPINC1 PLG F2 ATP4A ATP12A
37 myocardial infarction 28.3 SERPINC1 PLG MTHFR F2 ACE2
38 patent foramen ovale 28.1 SERPINC1 PLG MTHFR F2 CACNA1A ACE2
39 hypertension, essential 28.0 SERPINC1 PLG MTHFR F2 ATP4A ATP12A
40 nervous system disease 27.6 SERPINC1 POLG PLG MTHFR F2 CACNA1A
41 meniere disease 11.7
42 episodic ataxia, type 3 11.3
43 viral labyrinthitis 11.3
44 peripheral vertigo 11.3
45 vertigo, benign recurrent, 2 11.2
46 herpes zoster oticus 11.2
47 vestibular disease 11.1
48 vestibular neuronitis 11.1
49 acoustic neuroma 11.1
50 superior semicircular canal dehiscence 11.1

Comorbidity relations with Central Nervous System Origin Vertigo via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Central Nervous System Origin Vertigo:



Diseases related to Central Nervous System Origin Vertigo

Symptoms & Phenotypes for Central Nervous System Origin Vertigo

Symptoms:

11
  • vomiting
  • difficulty walking
  • nausea
  • dizziness

UMLS symptoms related to Central Nervous System Origin Vertigo:


vertigo

MGI Mouse Phenotypes related to Central Nervous System Origin Vertigo:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 ACE2 ATP12A ATP4A CACNA1A F2 MTHFR
2 growth/size/body region MP:0005378 9.91 ACE2 ATP12A ATP4A CACNA1A F2 MTHFR
3 digestive/alimentary MP:0005381 9.63 ACE2 ATP12A ATP4A F2 PLG POLG
4 mortality/aging MP:0010768 9.56 ACE2 ATP4A CACNA1A F2 MTHFR PLG
5 integument MP:0010771 9.1 ACE2 CACNA1A F2 MTHFR PLG POLG

Drugs & Therapeutics for Central Nervous System Origin Vertigo

Drugs for Central Nervous System Origin Vertigo (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
2
Calcium carbonate Approved, Investigational Phase 4 471-34-1
3
Histamine Approved, Investigational Phase 4 51-45-6 774
4
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
5
Dimenhydrinate Approved Phase 4 523-87-5 10660
6
Piracetam Approved, Investigational Phase 4 7491-74-9 4843
7
Phenol Approved, Experimental Phase 4 108-95-2 996
8
Ethanol Approved Phase 4 64-17-5 702
9
Glycerin Approved, Investigational Phase 4 56-81-5 753
10
Thymol Approved Phase 4 89-83-8 6989
11
Caffeine Approved Phase 4 58-08-2 2519
12
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
13
Diphenidol Approved, Investigational, Withdrawn Phase 4 972-02-1 3055
14
Tocopherol Approved, Investigational Phase 4 1406-66-2
15
Mecobalamin Approved, Investigational Phase 4 13422-55-4
16
Ginger Approved Phase 4
17
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
18
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
19
Montelukast Approved Phase 4 158966-92-8 5281040
20
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 4 59-02-9, 10191-41-0 2116 14985
21
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
23
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
24
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 24892734 16212801 44176380
25
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
26
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6 1130
27
Tocotrienol Investigational Phase 4 6829-55-6 9929901
28
Cobalamin Experimental Phase 4 13408-78-1 6857388
29 Dopamine Agents Phase 4
30 Anti-Ulcer Agents Phase 4
31 Antacids Phase 4
32 Calcium Supplement Phase 4
33 Antiemetics Phase 4
34
Histamine phosphate Phase 4 51-74-1 134614
35 Histamine H1 Antagonists Phase 4
36 Histamine Antagonists Phase 4
37 Vasodilator Agents Phase 4
38 Dopamine Antagonists Phase 4
39 Pharmaceutical Solutions Phase 4
40 Neuroprotective Agents Phase 4
41 Nootropic Agents Phase 4
42 Protective Agents Phase 4
43 Phosphodiesterase Inhibitors Phase 4
44 Antioxidants Phase 4
45 Central Nervous System Stimulants Phase 4
46 Vitamin B3 Phase 4
47 Nicotinic Acids Phase 4
48 Antimetabolites Phase 4
49 Hypolipidemic Agents Phase 4
50 Lipid Regulating Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 189)
# Name Status NCT ID Phase Drugs
1 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients With Headache and Dizziness or Epilepsy and Clinical Indication for an Angiography by Magnetic Imaging Unknown status NCT00132223 Phase 4 Contrast agent
2 Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in Benign Paroxysmal Positional Vertigo: A Prospective Multicenter Randomized Trial Completed NCT02031692 Phase 4 400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate
3 Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo: A Double Blind Randomized Clinical Trial Completed NCT01890538 Phase 4 Administration of 100 mg dimenhydrinate intravenous;2 g piracetam intravenous
4 Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo Completed NCT02253524 Phase 4 Dimenhydrinate;Metoclopramide
5 Randomized, Placebo-Controlled Evaluation of Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal Completed NCT00765635 Phase 4 drops intilation (Taponoto ® );drops intilation (Otocerum®);drops intilation (Placebo)
6 Effect of Caffeine Intake in Vestibular Function: A Randomized Triple-Blind Controlled Trial Completed NCT02825199 Phase 4
7 Effect of Stellate Ganglion Block on Meniere's Disease Completed NCT01574313 Phase 4 0.25mg, fludiazine;25mg [email protected] (diphenidol);200mg [email protected] (tocopherol nicotinate).
8 Double Blind Evaluation of Gamma-aminobutyric Acid Tartarate 100 mg, Glutamic Acid 100 mg, Dibasic Calcium Phosphate 50 mg, Thiamine Nitrate 25 mg, Pyridoxine Chloride 10 mg and Cyanocobalamin 5 mcg Versus Ginger for Vertigo-kinetosis Recruiting NCT05221892 Phase 4 Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin;Ginger
9 Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease Recruiting NCT04815187 Phase 4 Montelukast;Placebo
10 A Multicenter, Placebo-Controlled, Double-Blind Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation Withdrawn NCT00474409 Phase 4 Merislon
11 " National, Phase III, Radomized, Double-Blind, Double -Dummy, Controlled, Parallel to Evaluate Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) Soft Gel Capsules in the Control of Acute Vertigo Symphtoms From Peripheral Origin" Unknown status NCT02112578 Phase 3 Meclizine;Dimenhydrinate
12 Assessment of Acyclovir Efficacy Versus Placebo in Controlling Vertigo Attacks of Patients With Meniere's Disease Visited in Amiralam Hospital Unknown status NCT01729767 Phase 2, Phase 3 Acyclovir;Placebo
13 Randomized Multicenter Study of Treatment of Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT00810641 Phase 3
14 The Effectiveness Comparison of Three Different Methods for the Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo: Prospective, Double Blinded, Randomized, Multicenter Clinical Trial Completed NCT02029508 Phase 3
15 Treatment of Benign Paroxysmal Positional Vertigo With the Canalith Repositioning Procedure in Family Practice: A Randomized Controlled Trial Completed NCT00182273 Phase 3
16 Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo; Randomized Controlled Trial of Barbeque Rotation and Gufoni Maneuver Completed NCT01366430 Phase 3
17 Double-blind Placebo-controlled Multicenter Randomized Clinical Trial to Evaluate the Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg (JSC Valenta Pharm, Russia) in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo Completed NCT05430217 Phase 3 Buspirone;Placebo
18 Promethazine vs. Lorazepam for Treatment of Vertigo in the Emergency Department: A Randomized Clinical Trial Completed NCT01827293 Phase 3 Promethazine;Lorazepam
19 A Phase II/III Trial on Rizatriptan for Vestibular Migraine Completed NCT02447991 Phase 2, Phase 3 Rizatriptan;Placebo
20 Comparison of Efficacy of Metoclopramide , Promethazine and Prochloroperazine in the Treatment of Vertigo. Recruiting NCT05586763 Phase 3 Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)
21 Visual Feedback Goggle For The Treatment Of Benign Paroxysmal Positional Vertigo in a Randomized Single-Blind Study Unknown status NCT00729885 Phase 1, Phase 2
22 A Double Blinded Randomized Control Trial (RCT) to Evaluate the Effectiveness of Vitamin D Treatment in Lowering the Recurrence Rate of Benign Paroxysmal Positional Vertigo (BPPV) in Older Patients Unknown status NCT04578470 Phase 2 Vitamin D;Placebo
23 Lamotrigine for Ménière's Disease: a Double-blind, Placebo-controlled Pilot Study Completed NCT02158585 Phase 2 Lamotrigine;Placebo
24 Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT02046980 Phase 2
25 Treatments for Benign Paroxysmal Positional Vertigo (BPPV) Completed NCT00000359 Phase 2
26 Comparison of Treatment Efficacy of Automated Robotic Maneuvering System (RMS) Reposition Chair Versus Traditional Manual Repositioning Maneuvers in Benign Paroxysmal Positional Vertigo (BPPV) Completed NCT05352555 Phase 1, Phase 2
27 Multicenter Randomized Controlled Phase 2 Trial to Evaluate AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery (TRAVERS) Completed NCT03908567 Phase 2 Intranasal Drug;Oral Tablet
28 A Multicenter, Double-Blind, Phase Ⅱ Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo Caused By Posterior Circulation Infarction Completed NCT02299804 Phase 2 Levophencynonate Hydrochloric;Placebo
29 Effect of V0251 in Acute Vertigo Completed NCT01583738 Phase 2 V0251;placebo
30 A Randomized, Prospective, Double-Blind, Placebo-Controlled, Pilot Study to Assess the Effectiveness of a Combination of Lamotrigine and Bupropion to Treat Meniere's Disease Recruiting NCT05420350 Phase 2 Lamotrigine and Bupropion;Placebo
31 Effect of Jaeumgeonbi-Tang on Chronic Subjective Dizziness: A Randomized, Double-Blind, Parallel-group, Placebo-Controlled Trial Suspended NCT05482828 Phase 2 JGT (Jaeumgeonbi-Tang) tablet;Placebo tablet
32 Efficacy of Extended-release, Once Daily Tramadol for Post Operative in Ambulatory Shoulder Arthroscopy Terminated NCT02247648 Phase 2 tramadol;Placebo
33 Pharmacologic Dissection of Vestibular Migraine and Chronic Subjective Dizziness: A Double-Blind Parallel Group Trial Comparing Response to Verapamil Versus Sertraline Completed NCT01669304 Phase 1 Verapamil;Sertraline
34 Multicentre, Open Label, Phase I Clinical Trial to Evaluate the Safety of APSLXR for the Treatment of Vertigo of Vestibular Origin or Meniere's Disease Withdrawn NCT04674735 Phase 1 APSLXR
35 Do Migrainous Vertigo Patients Have More Hypersensitivity in Their Vestibular System Than Migraine Patients Without Vertigo? Unknown status NCT00901953
36 Comparison of the Treatment Outcomes of Posterior Canal Benign Paroxysmal Positional Vertigo (BPPV) With Canalith Repositioning Procedure (CRP): Single Versus Multiple Cycles Unknown status NCT02701218
37 Epley Manoeuvre for Posterior Semi-circular Canal Benign Paroxysmal Positional Vertigo in People With Multiple Sclerosis: Protocol of a Randomized Controlled Trial Unknown status NCT04578262
38 Efficacy of Postural Restriction in Treating Benign Paroxysmal Positional Vertigo Unknown status NCT02475239
39 Production of a Device to Obtain Continuous Ambulatory Vestibular Assessment (CAVA) - Dizziness Trial Unknown status NCT04026516
40 Randomized Controlled Trials for Treatment of Benign Paroxysmal Positional Vertigo Unknown status NCT01822002
41 Vestibular Function Evaluated by the Video Head Impulse Test (vHIT) and Vertigo Perceived by the Patients Before and After Cochlear Implant Surgery. Unknown status NCT02584361
42 The Use of Virtual Reality for the Treatment of Visual Vertigo. Unknown status NCT03020654
43 The Effect of Vestibular Exercise, With or Without Medication, in Managing Residual Dizziness After Successful Repositioning Maneuvers in Patients With Benign Paroxysmal Positional Vertigo Unknown status NCT03624283 Betahistine
44 Saccular Dilatation, Endolymphatic Hydrops and Vestibular Schwannoma : is Vertigo Really Correlated to the Tumor ? A Retrospective Study Based on FIESTA-C Sequence Using a 3 Tesla MRI Unknown status NCT03593577
45 Tailored Care for Somatoform Vertigo/Dizziness - From Diagnostics to Therapy Unknown status NCT02320851
46 Therapeutic Effects and Safety of Percutaneous Disc Decompression With Coblation Nucleoplasty in Cervical Vertigo Unknown status NCT03485768
47 Inactivity, Balance Problems and Fall Risk in Institutionalized Frail Elderly: What is the Impact of Benign Paroxysmal Positional Vertigo (BPPV) and Treatment Effectiveness? Unknown status NCT02905292
48 Vestibular Function and Vestibular Rehabilitation in Sudden Sensorneural Hearing Loss With Vertigo Unknown status NCT03431506
49 Semicircular Canals Dysfunction Among Patients Hospitalized at the Rehabilitation Department Unknown status NCT04447066
50 DeepDoc - Clinical Validation of an AI-based Decision Support System in the Early Diagnostic Evaluation of Neurological Diseases: a Prospective Multi-center Study Unknown status NCT04055766

Search NIH Clinical Center for Central Nervous System Origin Vertigo

Cochrane evidence based reviews: vertigo

Genetic Tests for Central Nervous System Origin Vertigo

Anatomical Context for Central Nervous System Origin Vertigo

Organs/tissues related to Central Nervous System Origin Vertigo:

MalaCards : Cerebellum, Brain, Liver, Eye

Publications for Central Nervous System Origin Vertigo

Articles related to Central Nervous System Origin Vertigo:

(show all 32)
# Title Authors PMID Year
1
Vestibular disorders in patients after COVID-19 infection. 62
36203969 2022
2
[Stabilometric diagnosis of vertigo in elderly patients with vestibular migraine.] 62
34998017 2021
3
A Rare Case of a Large, Deceitfully Quiet Brainstem Arteriovenous Malformation Presenting Only as Dizziness. 62
32754407 2020
4
Economic burden of vertigo: a systematic review. 62
31883042 2019
5
Description of a new type of benign recurrent vertigo of central origin. 62
29792304 2018
6
Vestibular evoked myogenic potentials and video head impulse test in patients with vertigo, dizziness and imbalance. 62
28242131 2017
7
[Benign paroxysmal positional vertigo]. 62
27070476 2016
8
[Vestibular neuritis: treatment and prognosis]. 62
24187751 2013
9
Infratentorial hygroma secondary to decompressive craniectomy after cerebellar infarction. 62
19830371 2009
10
[Causes and diagnostics of dizziness of central origin in children]. 62
20297643 2009
11
Central vestibular disorders. 62
17417688 2007
12
Clinical investigation on hypotensive patients with vertigo. 62
16816934 2006
13
[Results of transcranial Doppler examination of cerebral blood flow in children with vertigo]. 62
17348419 2006
14
[Additive treatment for central vestibular vertigo]. 62
15459763 2004
15
Differentiation between cerebellopontine angle tumors in cancer patients. 62
12438865 2002
16
Intravenous Lorazepam versus dimenhydrinate for treatment of vertigo in the emergency department: a randomized clinical trial. 62
11020677 2000
17
[Vertigo of central origin in a hypertensive patient]. 62
10730449 2000
18
The effectiveness of piracetam in vertigo. 62
10338110 1999
19
Prochlorperazine versus cinnarizine in cases of vertigo. 62
23119469 1998
20
Smooth pursuit neck torsion test: a specific test for cervical dizziness. 62
9455954 1998
21
Approach to the dizzy patient. 62
7874402 1994
22
Dyscalculia in patients with vertigo. 62
1670135 1990
23
Sudden vertigo of central origin. 62
3261109 1988
24
Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. 62
6141044 1984
25
[Phenomenology and differential diagnosis of peripheral and central vestibular vertigo]. 62
7019143 1981
26
Velocity of rapid eye movements and vertigo of central origin. 62
7224516 1981
27
The efficacy of piracetam in vertigo. A double-blind study in patients with vertigo of central origin. 62
7006617 1980
28
[Vertigo of central origin]. 62
4411493 1974
29
Vertigo of Central Origin. 62
19994159 1962
30
Vertigo of central origin. 62
13648026 1959
31
[Vertigo of central origin]. 62
14396083 1955
32
Case of Vertigo of Central Origin. 62
19983920 1924

Variations for Central Nervous System Origin Vertigo

Expression for Central Nervous System Origin Vertigo

Search GEO for disease gene expression data for Central Nervous System Origin Vertigo.

Pathways for Central Nervous System Origin Vertigo

GO Terms for Central Nervous System Origin Vertigo

Cellular components related to Central Nervous System Origin Vertigo according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.1 SERPINC1 PLG F2

Biological processes related to Central Nervous System Origin Vertigo according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular sodium ion homeostasis GO:0006883 9.76 ATP4A ATP12A
2 fibrinolysis GO:0042730 9.73 PLG F2
3 sodium ion export across plasma membrane GO:0036376 9.71 ATP4A ATP12A
4 cellular potassium ion homeostasis GO:0030007 9.67 ATP4A ATP12A
5 negative regulation of fibrinolysis GO:0051918 9.62 PLG F2
6 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.46 ATP4A ATP12A
7 regulation of blood coagulation GO:0030193 9.43 SERPINC1 F2
8 blood coagulation GO:0007596 9.43 SERPINC1 PLG F2
9 hemostasis GO:0007599 8.8 SERPINC1 PLG F2

Molecular functions related to Central Nervous System Origin Vertigo according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase-coupled monoatomic cation transmembrane transporter activity GO:0019829 9.56 ATP4A ATP12A
2 P-type sodium:potassium-exchanging transporter activity GO:0005391 9.46 ATP4A ATP12A
3 P-type potassium transmembrane transporter activity GO:0008556 8.96 ATP4A ATP12A
4 P-type potassium:proton transporter activity GO:0008900 8.92 ATP4A ATP12A

Sources for Central Nervous System Origin Vertigo

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....